The correct answer is Due to study design restrictions, an unfavorable total population size, the possibility of publication bias, and heterogeneity between studies, the quality of the evidence for the outcome of invasive fungal infection, superficial fungal infection, fungal colonization, and adverse events necessitating therapy cessation was low.
Ketoconazole and a placebo were evaluated in three trials. In one trial, anidulafungin was put up against a placebo. In one trial, caspofungin was compared to a placebo. Micafungin was put in two trials with a placebo. Amphotericin B and a placebo were evaluated in one trial. One experiment evaluated the impact of clotrimazole, ketoconazole, nystatin, and no treatment, while two trials compared the effect of nystatin to placebo. Four new research are awaiting classification, and there are two new ongoing trials. Participants in the RCTs were of both sexes, and they ranged widely in age, critical illness severity, and clinical features. Eleven trials reported pharmaceutical company financing, one trial claimed support from a government body. For the major review domains, the majority of the studies exhibited a generally unknown risk of bias.
Learn more about Amphotericin B here:-
brainly.com/question/4652591
#SPJ4
